BR9713974B1 - composiÇço farmacÊutica, processo para preparaÇço e uso da mesma. - Google Patents

composiÇço farmacÊutica, processo para preparaÇço e uso da mesma. Download PDF

Info

Publication number
BR9713974B1
BR9713974B1 BRPI9713974-2A BR9713974A BR9713974B1 BR 9713974 B1 BR9713974 B1 BR 9713974B1 BR 9713974 A BR9713974 A BR 9713974A BR 9713974 B1 BR9713974 B1 BR 9713974B1
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition according
drying
freeze
dried
Prior art date
Application number
BRPI9713974-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9713974A (pt
Inventor
Chris Bland
Gerald Steele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9713974A publication Critical patent/BR9713974A/pt
Publication of BR9713974B1 publication Critical patent/BR9713974B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI9713974-2A 1996-12-20 1997-12-11 composiÇço farmacÊutica, processo para preparaÇço e uso da mesma. BR9713974B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation
SE9604795-6 1996-12-20
PCT/SE1997/002068 WO1998028009A1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying

Publications (2)

Publication Number Publication Date
BR9713974A BR9713974A (pt) 2000-04-11
BR9713974B1 true BR9713974B1 (pt) 2010-02-23

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713974-2A BR9713974B1 (pt) 1996-12-20 1997-12-11 composiÇço farmacÊutica, processo para preparaÇço e uso da mesma.

Country Status (35)

Country Link
US (1) US6114313A (https=)
EP (1) EP1007094B1 (https=)
JP (1) JP4488538B2 (https=)
KR (1) KR100552880B1 (https=)
CN (1) CN1121875C (https=)
AR (1) AR010377A1 (https=)
AT (1) ATE221787T1 (https=)
AU (1) AU758857B2 (https=)
BR (1) BR9713974B1 (https=)
CA (1) CA2275153C (https=)
CZ (1) CZ300635B6 (https=)
DE (1) DE69714616T2 (https=)
DK (1) DK1007094T3 (https=)
EE (1) EE03857B1 (https=)
ES (1) ES2182133T3 (https=)
FR (1) FR15C0060I2 (https=)
HU (1) HU226616B1 (https=)
ID (1) ID21635A (https=)
IL (1) IL130449A0 (https=)
IS (1) IS1897B (https=)
MY (1) MY121982A (https=)
NO (1) NO327142B1 (https=)
NZ (1) NZ336027A (https=)
PL (1) PL190493B1 (https=)
PT (1) PT1007094E (https=)
RU (1) RU2205012C2 (https=)
SA (1) SA97180719B1 (https=)
SE (1) SE9604795D0 (https=)
SI (1) SI1007094T1 (https=)
SK (1) SK283137B6 (https=)
TR (1) TR199901412T2 (https=)
TW (1) TW522015B (https=)
UA (1) UA66779C2 (https=)
WO (1) WO1998028009A1 (https=)
ZA (1) ZA9711055B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
JP5947316B2 (ja) 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
EA034550B1 (ru) 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
CN115990138A (zh) 2015-01-14 2023-04-21 奇斯药制品公司 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (https=) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Atp凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
KR100315612B1 (ko) * 1993-02-10 2002-06-20 추후제출 N-알킬-2-치환아데노신트리포스페이트동족체

Also Published As

Publication number Publication date
BR9713974A (pt) 2000-04-11
CN1121875C (zh) 2003-09-24
SI1007094T1 (en) 2003-02-28
RU2205012C2 (ru) 2003-05-27
CN1240362A (zh) 2000-01-05
SA97180719B1 (ar) 2006-05-13
WO1998028009A1 (en) 1998-07-02
ES2182133T3 (es) 2003-03-01
KR20000069598A (ko) 2000-11-25
ID21635A (id) 1999-07-08
AU5351598A (en) 1998-07-17
DE69714616D1 (de) 2002-09-12
NO327142B1 (no) 2009-05-04
EE03857B1 (et) 2002-10-15
TW522015B (en) 2003-03-01
HU226616B1 (en) 2009-04-28
IS1897B (is) 2003-10-20
CZ220199A3 (cs) 1999-11-17
MY121982A (en) 2006-03-31
CA2275153A1 (en) 1998-07-02
HUP0000572A3 (en) 2002-10-28
AR010377A1 (es) 2000-06-07
ZA9711055B (en) 1998-07-08
ATE221787T1 (de) 2002-08-15
JP4488538B2 (ja) 2010-06-23
SE9604795D0 (sv) 1996-12-20
AU758857B2 (en) 2003-04-03
EP1007094A1 (en) 2000-06-14
TR199901412T2 (xx) 1999-08-23
NZ336027A (en) 2001-03-30
CZ300635B6 (cs) 2009-07-08
IL130449A0 (en) 2000-06-01
CA2275153C (en) 2008-03-25
HUP0000572A2 (hu) 2001-05-28
DE69714616T2 (de) 2003-04-03
FR15C0060I2 (fr) 2016-04-22
JP2001507022A (ja) 2001-05-29
FR15C0060I1 (https=) 2015-10-23
IS5064A (is) 1999-06-03
DK1007094T3 (da) 2002-10-28
NO993067L (no) 1999-08-09
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
EE9900260A (et) 2000-02-15
PT1007094E (pt) 2002-12-31
HK1026366A1 (en) 2000-12-15
SK283137B6 (sk) 2003-03-04
UA66779C2 (uk) 2004-06-15
EP1007094B1 (en) 2002-08-07
US6114313A (en) 2000-09-05
PL190493B1 (pl) 2005-12-30
PL334006A1 (en) 2000-01-31
NO993067D0 (no) 1999-06-21

Similar Documents

Publication Publication Date Title
BR9713974B1 (pt) composiÇço farmacÊutica, processo para preparaÇço e uso da mesma.
ES2273425T3 (es) Nueva formulacion.
CN118613251A (zh) 包含异𫫇唑啉衍生物的注射制剂及其制备方法
MXPA99005664A (en) Pharmaceutical compositions for freeze drying
HK1026366B (en) Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying
AU2003257524B2 (en) New formulation
HK1026429B (en) New formulation

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: ANULADA A PUBLICACAO DE INDEFERIMENTO POR TER CIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA UK LIMITED (GB)

Free format text: TRANSFERIDO DE: ASTRA PHARMACEUTICALS LIMITED

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23.02.2020